The NF-κB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1574-1582

  Walsby, Elisabeth J ^a   Pratt, Guy ^b   Hewamana, Saman ^a   Crooks, Peter A ^c   Burnett, Alan K ^a   Fegan, Chris ^a   Pepper, Chris ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; CD38 ANTIGEN; DOXORUBICIN; FIBRONECTIN; LC 1; MELPHALAN; SYNDECAN 1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LC 1 COMPOUND; LC-1 COMPOUND; PYRAZINE DERIVATIVE; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ADHESION; CELL KILLING; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN BINDING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CASPASE 3; CELL ADHESION; CELL DEATH; CELL LINE, TUMOR; DNA; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; PROTEIN BINDING; PYRAZINES; SESQUITERPENES; TRANSCRIPTION FACTOR RELA;

EID: 77953460057     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0104     Document Type: Article

References (42)

1. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007;20:597-612.
2. Vanderkerken K, Van CB, De GC, Vande BI, Asosingh K, Van RI. Homing of the myeloma cell clone. Acta Oncol 2000;39:771-6.
3. Dalton W, Anderson KC. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res 2006;12:6603-10. (Pubitemid 44876827)
4. Harousseau JL, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev 2002;16:245-53. (Pubitemid 35230787)
5. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31. (Pubitemid 43363369)
6. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3.
7. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
8. Hoffman A, Natoli G, Ghosh G. Transcriptional regulation via the NF-κ b signalling module. Oncogene 2006;25:6706-16. (Pubitemid 44657847)
9. Gilmore TD. Multiple myeloma: lusting for NF-κB. Cancer Cell 2007;12:95-7.
10. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30. (Pubitemid 47199123)
11. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007;12:131-44. (Pubitemid 47208626)
12. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309. (Pubitemid 40488635)
13. Suvannasankha A, Crean CD, Shanmugam R, et al. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res 2008;14:1814-22. (Pubitemid 351469468)
14. Steele AJ, Jones DT, Ganeshaguru K, et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 2006;20:1073-9. (Pubitemid 43797300)
15. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-κB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett 2009;19:4346-9.
16. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-35. (Pubitemid 351377809)
17. Hewamana S, Alghazal S, Lin TT, et al. The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111:4681-9.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. Alkylating agents induce activation of NFκB in multiple myeloma cells. Leuk Res 2008;32:1144-7.
20. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80. (Pubitemid 36302084)
21. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007;138:783-91. (Pubitemid 47313207)
22. Romagnoli M, Trichet V, David C, et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007;21:1070-8. (Pubitemid 46672084)
23. Vrana JA, Cleaveland ES, Eastman A, Craig RW. Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis 2006;11:1275-88. (Pubitemid 44043088)
24. Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004;125:156-61. (Pubitemid 38534966)
25. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR):role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.
26. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82. (Pubitemid 36722250)
27. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
28. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival in younger patients with multiple myeloma. Blood 2008;111:2521-6.
29. Yasui H, Hideshima T, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling casades in multiple myeloma. Br J Haematol 2005;132:385-97. (Pubitemid 43381614)
30. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996;87:1104-12. (Pubitemid 26043538)
31. Matsiades CS, Mitsiades N, Poulaski V, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83. (Pubitemid 35333000)
32. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell -derived factor-1α in multiple myeloma. Mol Cancer Ther 2002;1:539-44.
33. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148-57. (Pubitemid 38451693)
34. Ogata A, Chauhan D, Teoh G, et al. Il-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-21. (Pubitemid 127681011)
35. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat 3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:869-78. (Pubitemid 29077388)
36. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI-3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000. (Pubitemid 32955041)
37. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κ B (RelB/p50) in myeloma cells. Oncogene 2003;22:2417-21.
38. Hideshima T, Richardson P, Chauhan D, et al. The proteosome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6. (Pubitemid 32691956)
39. Matsui M, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-7. (Pubitemid 351380120)
40. Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591-9.
41. Romagnoli M, Séveno C, Wuillème-Toumi S, et al. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma. Br J Haematol 2009;145:180-9.
42. Li QF, Wu CT, Guo Q, Wang H, Wang LS. Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis. Biochem Biophys Res Commun 2008;371:159-62.